Department of Surgery, Hanyang University Guri Hospital, Guri, Republic of Korea.
Department of Surgery, Dongguk University Medical Center, Gyeongju, Republic of Korea.
Indian J Pathol Microbiol. 2020 Apr-Jun;63(2):221-225. doi: 10.4103/IJPM.IJPM_822_19.
The function of ASXL1 in colorectal cancer (CRC) has not been investigated yet.
The purpose of this study was to investigate the clinicopathological and prognostic impact of ASXL1 expression on CRC.
The intensity of expression was scored as 0-3, and the extent of staining was scored as 0-4, based on the percentage of positive cells. The immunoreactivity score (IRS) was calculated by multiplying the two scores.
We performed immunohistochemical staining of ASXL1 using tissue microarrays of 408 CRCs, 46 normal colonic mucosae, 48 adenomas, and 92 metastatic lymph nodes.
Clinicopathological variables were compared using Fisher's exact test, χ-test, or unpaired Student's t-test, depending on the nature of the data.
A negative expression of ASXL1 was observed in 10.9% of normal mucosae, 27.1% of adenomas, 55.6% of adenocarcinomas, and 71.7% of metastatic lymph nodes (P < 0.001). With respect to the IRS cut-off score, lymph node metastasis and lymphatic invasion were more frequent in the IRS 0-6 group than in the IRS 8-12 group (56.3% vs. 33.3%, P = 0.034; 56.0% vs. 33.3%, P = 0.035). The 5-year disease-free survival rate was significantly lower in patients with IRS 0-6 group than those with IRS 8-12 group (78.7 ± 2.5 vs. 100%, P = 0.034).
ASXL1 might act as a tumor suppressor in CRC. The loss of ASXL1 expression might be associated with lymph node metastasis and lymphatic invasion in CRC.
ASXL1 在结直肠癌（CRC）中的功能尚未得到研究。
本研究旨在探讨 ASXL1 表达对 CRC 的临床病理和预后影响。
根据阳性细胞的百分比，将表达强度评分评为 0-3，将染色程度评分评为 0-4。免疫反应评分（IRS）通过将两个评分相乘计算得出。
我们使用 408 例 CRC、46 例正常结肠黏膜、48 例腺瘤和 92 例转移性淋巴结的组织微阵列进行 ASXL1 的免疫组织化学染色。
根据数据的性质，使用 Fisher 确切检验、χ 检验或未配对学生 t 检验比较临床病理变量。
正常黏膜中观察到 ASXL1 阴性表达的比例为 10.9%，腺瘤为 27.1%，腺癌为 55.6%，转移性淋巴结为 71.7%（P<0.001）。就 IRS 截断评分而言，IRS 0-6 组的淋巴结转移和淋巴管浸润比 IRS 8-12 组更频繁（56.3%比 33.3%，P=0.034；56.0%比 33.3%，P=0.035）。IRS 0-6 组患者的 5 年无病生存率明显低于 IRS 8-12 组（78.7±2.5 比 100%，P=0.034）。
ASXL1 可能在 CRC 中起肿瘤抑制作用。ASXL1 表达的丧失可能与 CRC 中的淋巴结转移和淋巴管浸润有关。
